Madison Vaccines To Be Used In Clinical Trial Of A New Combination Approach To Immunotherapy Funded By The Prostate Cancer Foundation And The Movember Foundation
8/28/2014 12:06:20 PM
MADISON, Wis.--(BUSINESS WIRE)--Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, today said its lead product candidate MVI-816 (pTVG-HP) will be used in a clinical trial testing a two-pronged immunotherapy approach to treat metastatic prostate cancer. The vaccine is intended to stimulate the immune system to fight the cancer cells while a PD-1 pathway inhibitor is designed to prevent the cancer cells from camouflaging themselves to expose the cancer cells to attack. The trial will be conducted with a $1.5 million 2014 Movember-Prostate Cancer Foundation (PCF) Challenge Award funded by the Movember Foundation and supported by the Movember-PCF Challenge Award program. The research will be conducted under the direction of Douglas McNeel, M.D., Ph.D., Professor of Medicine at the University of Wisconsin-Madison.
Help employers find you! Check out all the jobs and post your resume.
comments powered by